<DOC>
	<DOCNO>NCT00017329</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness PS-341 treating patient metastatic kidney cancer .</brief_summary>
	<brief_title>PS-341 Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy PS-341 patient metastatic renal cell carcinoma . - Determine safety drug patient . OUTLINE : This open-label study . Patients receive PS-341 IV 3-5 second twice weekly 2 week . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients follow 2 week . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 6-19 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Metastatic disease Unidimensionally measurable disease No brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70100 % Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL ALT/AST great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Other : No preexist neuropathy grade 1 great No malignancy within past 5 year , except completely resect basal cell skin cancer , unless treat potentially curative therapy low risk recurrence Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No concurrent biologic therapy Chemotherapy : No prior cytotoxic therapy No concurrent cytotoxic therapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : At least 4 week since prior major surgery Other : No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>